Novo Nordisk (NOVOB DC) says the price dynamic for wegovy injectable in the US is now is the same as what we started the year with

Novo has form here: through past quarters the stock has been sensitive to any signal on net pricing, rebates, and the mix shift between branded supply, compounded competition, and cash-pay channels, with guidance language on US price dynamics repeatedly moving the shares more than headline volumes. The remark that the dynamic is now back to where the year began reads as an attempt to frame earlier softness as contained rather than a new trend, a formulation management teams in this position have used before when stabilising expectations mid-year. The distinction that matters is between gross-to-net pressure from competition and contracting, which tends to persist, and transitory effects from channel or supply normalisation, which reverse; the comment is ambiguous between the two. Worth watching are the next quarterly disclosures on US net sales per unit and any peer commentary from the competing incretin franchise, since the pair have historically traded as a read-across on shared category pricing.